US · Healthcare · Biotechnology
EPS came in at -0.07 against a street estimate of -0.05 — a miss of 40.0%.
Analysts rate Ardelyx Inc a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $12.90.
| Fund | Stake |
|---|---|
| BlackRock Inc | 9.10% |
| Rubric Capital Management LP | 6.28% |
| Millennium Management LLC | 5.38% |
| State Street Corp | 5.17% |
| Vanguard Capital Management, LLC | 4.06% |
| Delaware Management Holdings Inc | 3.70% |
| HHG PLC | 3.24% |
| Vanguard Portfolio Management, LLC | 3.11% |
| Document | Date |
|---|---|
| Company announcement · Q3 2026 ARDELYX, INC. - 8-K SUMMARY OTHER NOTABLE POINTS • Chief Commercial Officer Resignation: Eric Foster resigned as Chief Commercial Officer effective | 2026-08-17 |
| Quarterly report · Q2 2026 ARDELYX, INC. – FORM 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Total revenues (6 months ended June 30, 2026): $215.4 million vs. $171.8 million (202 | 2026-08-06 |
| Results announced · Q3 2026 ARDELYX Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Q2 2026 total product revenue: $118.1 million, up 31% year-over-year • IBSRELA Q2 reven | 2026-08-06 |
| Current report · Q2 2026 ARDELYX, INC. - FORM 8-K SUMMARY (June 29, 2026) HEADLINE NUMBERS • Company received $50.0 million in debt funding on June 29, 2026 • Loan maturity | 2026-07-02 |
| Board / officer change · Q2 2026 ARDELYX, INC. - FORM 8-K SUMMARY (June 16, 2026) HEADLINE NUMBERS • Outstanding shares as of record date (April 22, 2026): 247,029,387 shares of com | 2026-06-17 |
| Quarterly report · Q1 2026 ARDELYX, INC. – Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Product sales (net): $93.4 million in Q1 2026 vs. $67.8 million in Q1 2025 (37.7% incre | 2026-04-30 |
| Proxy statement · Q2 2026 ARDELYX, INC. – PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGES • Michael Raab (CEO) total compensation figure not explicitly stated in prov | 2026-04-29 |
| Annual report FY2025 ARDELYX, INC. – FORM 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization (as of June 30, 2025): $923.7 million based on $3.92 | 2026-02-19 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ardelyx Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.